Inceptive
Series A
RNA design firm using deep learning and high-throughput experiments to create innovative medicines and biotechnologies.
Founded
2021RNA design firm using deep learning and high-throughput experiments to create innovative medicines and biotechnologies.
Inceptive, founded with the mission to revolutionize the field of biotechnology, focuses on designing RNA molecules using advanced deep learning techniques combined with high-throughput experiments. The company aims to create powerful biological software that enables the rational design of novel and broadly accessible medicines and biotechnologies, pushing the boundaries of what is currently achievable in the field. Their market focus includes pharmaceutical companies and research institutions looking to develop innovative treatments and biotechnological solutions.
Notable individuals affiliated with Inceptive include experts in computational biology and biotechnology, though specific names are not provided. The company has garnered attention for its cutting-edge approach to RNA design, leveraging artificial intelligence to accelerate the development of new therapies. Inceptive's impact is evident in its potential to transform medicine by making advanced biotechnologies more accessible and effective, positioning itself as a leader in the next generation of medical innovation.
Companies similar to Inceptive include Atomic AI, Wayfinder Biosciences, Laronde and Nextrna Therapeutics.
Inceptive was founded in 2021.
Inceptive's headquarters is located in Palo Alto, CA, US.
Inceptive's most recent funding round was for $100M (USD) in September 2023.
As of Sep 7, 2023, Inceptive has raised a total of $120M (USD).
Inceptive has 29 employees as of Feb 4, 2024.
Laronde
laronde.bio
